The Food and Drug Administration is ramping up technology adoption, and prioritizing AI and data strategies to ensure safety of new interventions and medical devices, improve workflows and ultimately deliver on its public health mission. Arunan Skandarajah, an FDA Presidential Innovation Fellow who believes in the power of equitable digital tools, discusses how he is innovating FDA’s regulatory processes to drive greater efficiencies.
HealthCast
Season 2
Episode 30
36m listen
How AI, Data Are Boosting FDA’s Regulatory Processes
Share
A Presidential Innovation Fellow is helping the agency improve workflows and ultimately ensure safety of the drugs and treatments it regulates.
-
Arunan Skandarajah Presidential Innovation Fellow FDA
Related Content
-
OPM Extends Tech Force Deadline as Program Tests New Federal Hiring Model
High demand prompted OPM to extend Tech Force applications to Feb. 2 as the agency pilots centralized, skills-based hiring.
5m read -
FDA Outlines AI Principles for Drug Development
New FDA guidance outlines 10 principles for using AI in drug research, development and manufacturing, developed with European regulators.
3m read -
Federal AI Enters a ‘Storming Phase’ Under the Genesis Mission
National labs are working to reduce complexity, connect compute and deploy assured autonomy to speed AI research and deployment.
3m read -
Agencies Turn to Industry to Scale AI, Develop Federal Workforce
Federal IT leaders say industry partnerships are critical to overcoming workforce and technical challenges in AI adoption.
3m read
